30-Sep-2015 12:00 AM
35399
Birth asphyxia is a common cause of neonatal mortality. Identification of severity of asphyxia is vital for prompt management. Biomarkers can be used for timely diagnosis of asphyxia and also helps in prognosis. Serum, CSF, urine, cord blood & magnetic resonance biomarkers for asphyxia in neonates have been studied. Cytokines like IL-6 in CSF, NSE in CSF, Protein S-100b in serum, urine & cord blood, LDH in serum and saliva, CK in serum and urine, cord BDNF, Urinary UA/Cr ratio, GFAP, Glutamate in CSF, PGE2, AST, ALT, Activin A have been studied with varied diagnostic accuracy and feasibility. Research directed towards newer biomarkers like NPBI, Hypoxanthine, total hydroperoxides, AOPP, UCHL-1 & pNFH-1 for early identification of severe asphyxia have shown promising results. Cardiac biomarkers like Troponin T & I, BNP, CK-MB may aid in longterm outcome. NRBC count still remains as the oldest and best-described biomarker of asphyxia. Use of Proton & Nuclear Magnetic Resonance Spectroscopy on day 1 apart from conventional MRI have opened a new era of MR Biomarkers in neonatal asphyxia. Early identification of severity of asphyxia with judicious use of biomarkers can make a huge difference in the management and outcome of birth asphyxia.
View Full Article | Download PDF